[go: up one dir, main page]

UY27439A1 - Procedimiento para sintetizar un conjunto de oligomero-polipeptido insulina, conjugado oligomero-polipeptido de proinsulina, composicion de conjugado oligomero-insulina, procedimiento para sintetizar un conjugado oligomero-polipeptido c-peptido, conj - Google Patents

Procedimiento para sintetizar un conjunto de oligomero-polipeptido insulina, conjugado oligomero-polipeptido de proinsulina, composicion de conjugado oligomero-insulina, procedimiento para sintetizar un conjugado oligomero-polipeptido c-peptido, conj

Info

Publication number
UY27439A1
UY27439A1 UY27439A UY27439A UY27439A1 UY 27439 A1 UY27439 A1 UY 27439A1 UY 27439 A UY27439 A UY 27439A UY 27439 A UY27439 A UY 27439A UY 27439 A1 UY27439 A1 UY 27439A1
Authority
UY
Uruguay
Prior art keywords
oligomero
polypeptide
conjugate
insulin
proinsulin
Prior art date
Application number
UY27439A
Other languages
English (en)
Inventor
Richard Soltero
Balasingham Radhakrishnan
Nnochiri N Ekwuribe
Original Assignee
Nobex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/036,744 external-priority patent/US6913903B2/en
Application filed by Nobex Corp filed Critical Nobex Corp
Publication of UY27439A1 publication Critical patent/UY27439A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe un procedimiento para sintetizar polipcptidos de proinsulina que comprende el contactado de un polipcptido de proinsulina que incluye un polipcptido insulina acoplado a uno o mrs pcptidos mediante enlaces peptidicos capaces de ser cortados para dar el polipcptido insulina, con un olignmero bajo condiciones suficientes para acoplar el olignmero a la parte de polipcptido insulina del polipcptido de proinsulina para proveer un conjugado olignmero-polipcptido de proinsulina y cortar uno o mrs pcptidos del conjugado oligomero polipcptido de insulina. Tambicn se describen procedimientos para sintetizar conjugados oligomero-polipcptido de proinsulina.
UY27439A 2001-09-07 2002-09-06 Procedimiento para sintetizar un conjunto de oligomero-polipeptido insulina, conjugado oligomero-polipeptido de proinsulina, composicion de conjugado oligomero-insulina, procedimiento para sintetizar un conjugado oligomero-polipeptido c-peptido, conj UY27439A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31819701P 2001-09-07 2001-09-07
US10/036,744 US6913903B2 (en) 2001-09-07 2001-12-21 Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US34946202P 2002-01-18 2002-01-18

Publications (1)

Publication Number Publication Date
UY27439A1 true UY27439A1 (es) 2003-04-30

Family

ID=27365090

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27439A UY27439A1 (es) 2001-09-07 2002-09-06 Procedimiento para sintetizar un conjunto de oligomero-polipeptido insulina, conjugado oligomero-polipeptido de proinsulina, composicion de conjugado oligomero-insulina, procedimiento para sintetizar un conjugado oligomero-polipeptido c-peptido, conj

Country Status (16)

Country Link
EP (1) EP1430082B1 (es)
JP (1) JP4318546B2 (es)
AR (1) AR036449A1 (es)
AT (1) ATE446971T1 (es)
AU (1) AU2002329989A1 (es)
CY (1) CY1110640T1 (es)
DE (1) DE60234198D1 (es)
DK (1) DK1430082T3 (es)
ES (1) ES2333781T3 (es)
MY (1) MY127575A (es)
PE (1) PE20030536A1 (es)
PT (1) PT1430082E (es)
SA (1) SA02230453B1 (es)
SI (1) SI1430082T1 (es)
UY (1) UY27439A1 (es)
WO (1) WO2003022996A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7648962B2 (en) 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
DE60331584D1 (de) 2002-11-26 2010-04-15 Biocon Ltd Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen
PT1773878E (pt) * 2004-07-19 2015-06-05 Biocon Ltd Conjugados de insulina-oligómero, formulaçôes e usos dos mesmos
CA2611836A1 (en) * 2005-06-13 2006-12-21 Nastech Pharmaceutical Company Inc. Transmucosal delivery of peptide derivatives
JP5047978B2 (ja) * 2005-10-13 2012-10-10 バイオコン・リミテッド インスリン複合体の調製のための方法
CN101573133B (zh) 2006-07-31 2014-08-27 诺沃-诺迪斯克有限公司 Peg化延长的胰岛素
PL2074141T3 (pl) 2006-09-22 2017-02-28 Novo Nordisk A/S Analogi insuliny oporne na proteazę
JP5496082B2 (ja) 2007-04-30 2014-05-21 ノボ・ノルデイスク・エー／エス タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
JP5749155B2 (ja) 2008-03-18 2015-07-15 ノボ・ノルデイスク・エー／エス プロテアーゼ安定化アシル化インスリンアナログ
NZ603399A (en) 2010-05-17 2014-09-26 Cebix Inc Pegylated c-peptide
CA2870313A1 (en) 2012-04-11 2013-10-17 Novo Nordisk A/S Insulin formulations
CN105636979B (zh) 2013-10-07 2020-01-10 诺和诺德股份有限公司 胰岛素类似物的新衍生物
US20180169190A1 (en) 2016-12-16 2018-06-21 Novo Nordisk A/S Insulin containing pharmaceutical compositions
CN112312923A (zh) * 2018-06-18 2021-02-02 拜康有限公司 控制对象的餐后葡萄糖水平的方法和用途
CN113087623A (zh) * 2021-04-13 2021-07-09 苏州昊帆生物股份有限公司 一种8-溴辛酸乙酯的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4431740A (en) * 1979-09-12 1984-02-14 The Regents Of The University Of California DNA Transfer vector and transformed microorganism containing human proinsulin and pre-proinsulin genes
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
EP0792290B1 (en) 1993-09-17 2001-08-29 Novo Nordisk A/S Acylated insulin
US5646242A (en) 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5631347A (en) * 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US6323311B1 (en) * 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same

Also Published As

Publication number Publication date
JP4318546B2 (ja) 2009-08-26
EP1430082A2 (en) 2004-06-23
SI1430082T1 (sl) 2010-02-26
WO2003022996A3 (en) 2003-12-31
DK1430082T3 (da) 2010-01-18
PT1430082E (pt) 2010-01-15
JP2005502353A (ja) 2005-01-27
WO2003022996A2 (en) 2003-03-20
DE60234198D1 (de) 2009-12-10
PE20030536A1 (es) 2003-07-03
EP1430082A4 (en) 2004-11-24
CY1110640T1 (el) 2015-04-29
MY127575A (en) 2006-12-29
AR036449A1 (es) 2004-09-08
AU2002329989A1 (en) 2003-03-24
SA02230453B1 (ar) 2008-02-05
EP1430082B1 (en) 2009-10-28
ES2333781T3 (es) 2010-03-01
ATE446971T1 (de) 2009-11-15

Similar Documents

Publication Publication Date Title
UY27439A1 (es) Procedimiento para sintetizar un conjunto de oligomero-polipeptido insulina, conjugado oligomero-polipeptido de proinsulina, composicion de conjugado oligomero-insulina, procedimiento para sintetizar un conjugado oligomero-polipeptido c-peptido, conj
DK1144607T5 (da) Fremgangsmåde til præsentation af (poly)peptider/proteiner på bakteriofage partikler via disulfidbindinger
NO20031049L (no) Syntetiske erytropoese-stimulerende proteiner
NZ521396A (en) Fusion proteins comprising two or more Neisseria polypeptides
AU2007325952A8 (en) Cell-free synthesis of proteins containing unnatural amino acids
EP2284191A3 (en) Process for the preparation of hGH
WO2002002597A3 (en) Peptide extended glycosylated polypeptides
WO2005044839A3 (en) Stabilized alpha helical peptides and uses thereof
AU2003239659A1 (en) Peptide epitopes common to antigens of the same multigene family
EP1530637A4 (en) SUBTILISIN CARLSBERG PROTEINS WITH REDUCED IMMUNOGENICITY
IL153943A0 (en) SUBSTRATES AND ASSAYS FOR beta-SECRETASE ACTIVITY
DE69317886D1 (de) Neue propoxyphenderivate sowie deren protein-und polypeptidlabels und-konjugate
DE60039049D1 (de) Erhöhte expression von proteinen mittels gfp
MXPA04000648A (es) Identificacion de antigenos especificos del tumor por medio de seleccion de bibliotecas de acido desoxirribonucleico complementario con sueros y uso de antigenos en tecnicas de formacion de imagenes de diagnostico.
CO5271650A1 (es) Peptidos modificados y peptidomimeticos para el uso en inmunoterapia
SE9604108D0 (sv) A method for the labelling of polypeptides and novel labelled polypeptides
NO982227D0 (no) Urogenitalcarcinom-TPL komplekspeptider og antistoffer derav
AU2003260546A1 (en) Device for the presentation of peptides or proteins, method for the preparation and use thereof
AU2003273953A1 (en) Method for synthesizing peptides comprising at least one glycine molecule
ATE414717T1 (de) Neuromedin u delta polypeptide
ES1050159U (es) Portalamparas de interperie perfeccionado.
UY25951A1 (es) Polipéptidos receptores p75 (tipo ii) de factor de necrosis tumoral purificados

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20190110

VENC Patent expired

Effective date: 20220906